Speaker illustration

Ms Feby Fariska Savira

Monash University, Melbourne (Australia)

Feby is a final year PhD student in Monash University, Melbourne, Australia. Her research is focussed on novel treatments for cardiorenal syndrome and mechanistic studies of non-conventional risk factors such as uraemic toxins using laboratory-based experiments. Feby is also involved in projects utilising health economic modelling, including life table models projecting the productivity impact of cardiovascular and renal diseases, as well as decision analytic model of novel pharmacotherapies for cardiovascular disease aimed to inform decision makers. Having attained a unique dual proficiency in preclinical studies and economic evaluations, her goal is to become a health economist working in the preclinical translation of novel therapies to guide their potential clinical utility, particularly for chronic diseases such as cardiovascular disease.

Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Pharmacotherapy

Session: Chronic Heart Failure ePosters

Thumbnail

The impact of coronary heart disease on productivity in Australia over ten years

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Prevention

Session: Coronary Artery Disease (Chronic) ePosters

Thumbnail

Inhibition of apoptosis signal-regulating kinase 1 ameliorates cardiac dysfunction by reducing hypertrophy and fibrosis in a rat model of cardiorenal syndrome

Event: Heart Failure 2019 - 6th World Congress on Acute Heart Failure

Topic: Cardiovascular Pharmacotherapy, Other

Session: Basic science - Cardiomyopathies

Thumbnail

This platform is supported by

logo Novo Nordisk